6/6/2014 6:58:28 AM
Syndax Pharmaceuticals, a late-stage biotech developing a novel therapy for resistant breast cancer, announced terms for its IPO on Thursday. The Waltham, MA-based company plans to raise $60 million by offering 4.3 million shares at a price range of $13 to $15. At the midpoint of the proposed range, it would command a fully diluted market value of $179 million.
Help employers find you! Check out all the jobs and post your resume.
comments powered by